Treatment with extracts of Uncaria tomentosa promotes apoptosis in the human breast cancer cell line, MCF7. by Aljehani, Areej
 TREATMENT WITH EXTRACTS OF UNCARIA TOMENTOSA 
PROMOTES APOPTOSIS IN THE HUMAN BREAST CANCER 
CELL LINE, MCF7 
 
 
 
 
 
By  
 
 
 
Areej Aljehani 
 
 
 
A thesis submitted in partial fulfillment 
of the requirements for the degree of 
Master of Science (MSc) in Biology 
 
 
 
 
The Faculty of Graduate Studies 
Laurentian University 
Sudbury, Ontario, Canada 
 
 
 
 
© Areej Aljehani, 2015 
 
THESIS DEFENCE COMMITTEE/COMITÉ DE SOUTENANCE DE THÈSE 
Laurentian Université/Université Laurentienne 
Faculty of Graduate Studies/Faculté des études supérieures 
 
Title of Thesis     
Titre de la thèse   TREATMENT WITH EXTRACTS OF UNCARIA TOMENTOSA PROMOTES  
    APOPTOSIS IN THE HUMAN BREAST CANCER CELL LINE, MCF7 
 
Name of Candidate   
Nom du candidat    Aljehani, Areej 
       
Degree                            
Diplôme                            Master of Science 
 
Department/Program    Date of Defence    August 10, 2015 
Département/Programme  Biology   Date de la soutenance  
                                                       
APPROVED/APPROUVÉ 
 
Thesis Examiners/Examinateurs de thèse: 
                                                      
Dr. Robert Lafrenie  
(Supervisor/Directeur(trice) de thèse) 
 
Dr. Kabwe Nkongolo    
(Committee member/Membre du comité)    
        
Dr. Mazen Saleh      
(Committee member/Membre du comité)    
      Approved for the Faculty of Graduate Studies 
      Approuvé pour la Faculté des études supérieures 
       Dr. David Lesbarrères 
      Monsieur David Lesbarrères 
Dr. Kelly Meckling                          Acting Dean, Faculty of Graduate Studies 
(External Examiner/Examinateur externe)   Doyen intérimaire, Faculté des études supérieures 
 
                                                 
ACCESSIBILITY CLAUSE AND PERMISSION TO USE 
 
I, Areej Aljehani, hereby grant to Laurentian University and/or its agents the non-exclusive license to archive and 
make accessible my thesis, dissertation, or project report in whole or in part in all forms of media, now or for the 
duration of my copyright ownership. I retain all other ownership rights to the copyright of the thesis, dissertation or 
project report. I also reserve the right to use in future works (such as articles or books) all or part of this thesis, 
dissertation, or project report. I further agree that permission for copying of this thesis in any manner, in whole or in 
part, for scholarly purposes may be granted by the professor or professors who supervised my thesis work or, in their 
absence, by the Head of the Department in which my thesis work was done. It is understood that any copying or 
publication or use of this thesis or parts thereof for financial gain shall not be allowed without my written 
permission. It is also understood that this copy is being made available in this form by the authority of the copyright 
owner solely for the purpose of private study and research and may not be copied or reproduced except as permitted 
by the copyright laws without written authority from the copyright owner. 
 
 
 
 
ii 
Abstract 
 
      Uncaria tomentosa is a medicinal plant native to Peru which has been used 
traditionally for the treatment of various inflammatory disorders and cancer. Some 
studies have shown that treatment with Uncaria tomentosa promotes repair of cellular 
DNA in patients treated with chemotherapy drugs, preventing mutations and cell damage. 
Treatment with Uncaria tomentosa also inhibits inflammatory responses by inhibiting the 
proliferation of T and B-lymphocytes and decreasing the production of pro-inflammatory 
cytokines (IL-1, IL-6, and TNF-α). We have examined the effects of Uncaria tomentosa 
extracts on the growth of malignant cells such as MCF-7 and MDA-MB-231 cells, human 
breast cancer cell lines and non-malignant cells such as HBL-100, HEK 293T and HSG 
cells. Our results have shown that treatment of malignant cells and non-malignant cells 
with Uncaria tomentosa extracts inhibits their proliferation and promotes cell death in a 
dose-dependent manner. Further, extracts produced by boiling the ground bark in 70% 
ethanol are much more effective than extracts produced by boiling in water. Uncaria 
tomentosa-ethanol extracts potently induce cellular apoptosis as measured by changes in 
cell morphology, chromatin condensation (Acridine Orange/Ethidium Bromide staining 
assay) and DNA fragmentation (TUNEL assays) within 24 h of treatment. Overall, 
Uncaria tomentosa appeared to kill breast cancer cells effectively in vitro by increasing 
cellular apoptosis.  
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Chapter 1: Introduction   
1.1. Cancer  
Cancer is a worldwide killer; is a primary cause of death among many populations 
and is a major health burden in Canada. Cancer accounts for about a quarter of all deaths 
in Canada and is the second common reason for death after heart disease (Canadian 
Cancer Society, 2014). Almost half of Canadians will be diagnosed with cancer at some 
time during their lives. According to estimates in 2014, 191,300 cases of cancer were 
diagnosed in all ages, mostly over the age 50, and most of these cases were lung, breast, 
prostate and colorectal cancers. By 2020, the population worldwide is expected to have 
risen to 7.5 billion; approximately 15 million of this number will be diagnosed with 
cancer and 12 million cancer patients will die from different types of cancer (Anand et 
al., 2008). 
Cancer can be defined simply as uncontrolled cell division with the ability to 
spread either by invasion or metastases (Gaaib et al., 2014). Invasion refers to the 
movement of cancer cells from the primary site to surrounding tissues (Carey et al., 
2012). Metastasis is defined as the transported of malignant cells to distant organ of the 
body which is the main reason for cancer related-mortality (Banfalvi, 2012) 
Cancer is a complex disease initiated in normal cells because of a series of genetic 
changes such as activation of oncogenes or inactivation of tumour suppressor genes and 
epigenetic changes that promote the stimulation of cell proliferation (Weinberg, 1989; 
Vogelsein and Kinzler, 2004). It involves abnormal cell growth and proliferation through 
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a variety of pathways leading to tumour formation with the potential to spread throughout 
the body, which is called metastases (Orr et al., 2000).  
The formation of cancer includes a multistep process cellular and molecular 
which involving mutation and uncontrolled cell division (Weinberg, 1989; 2007). These 
processes take many years to develop. Fundamentally, cancer is a genetic disease that 
arises from the accumulation of multiple mutations and altered expression of genes in the 
normal cells leading misbehaves to these cells and additional DNA damaged (Vogelstein 
and Kinzler, 2004).  
Changes in the activity of various genes and proteins that regulate cell growth and 
differentiation are involved in the progressive transformation of normal cells into highly 
malignant cells (Weinberg, 1989; 2007; Vogelstein and Kinzler, 2004). The malignant 
cell is characterized by specific properties: resistance to apoptosis; invasive cell division, 
increased cell mobility, and metastases (Baba and Câtoi, 2007). However, not all tumours 
are malignant. There are two types of tumours; benign or malignant with benign tumours 
defined as lacking the ability or invade or spread. Most malignant tumours are 
carcinomas, which represent 90% of human cancer and arise from epithelial tissues such 
as those in skin, lungs, and mammary glands. Unlike carcinomas, sarcomas are 
malignancies that occur at lower frequency and arise from non-epithelial cells such as 
osteoblasts and fibroblasts (mesophyll cells) (Weinberg, 2007). 
Different internal factors and acquired factors contribute to the development of 
human cancers.  In most cases, cancers are largely the result of exposure to 
environmental factors and unhealthy lifestyle (90–95%). The direct contribution of 
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genetic predisposition such as inherited mutation and hormones is estimated at 5–10% 
(Frank, 2004). 
Environmental carcinogens, defined broadly to include tobacco use, diet, sun 
exposure, radiation, stress and infectious diseases all enhance cancer risks. Unhealthy 
lifestyle which known as lack of activity, obesity, poor diet and alcohol consumption also 
contribute to the formation of tumours. In other words, the process of tumour formation is 
a multifactorial and results from a complex interaction between several factors that 
influence the development of cancer particularly in an ageing population (McPherson et 
al., 2000).  
 Improving survival rates and decreasing mortality by increasing prevention 
efforts leads to reduced incidence rates or result in earlier diagnosis and treatment is the 
current goal of most anticancer programs (Canadian Cancer Statistics, 2013).  
 1.2.  Breast cancer  
Breast cancer is the most commonly cancer diagnosed among Canadian females 
and is the second most frequent type of cancer that increases the mortality rate in women 
(Canadian Cancer Statistics, 2013). Breast cancer has been the subject of many 
epidemiological and genetic research studies, which has shown it is a heterogeneous 
group of diseases. Male breast cancer is less common and accounts for 1% of breast 
cancer cases and deaths. However, the mortality of this disease hasn’t changed for the 
past five decades among the female populations (Russo, 2000). According to the 
Canadian Cancer Society, breast cancer is the most frequently cancer in the Canadian 
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women, with an estimated 24,400 new cases diagnosed in 2014 and 5000 deaths. Despite 
importance advances in early diagnosis and treatment, it continues to develop and is the 
most frequent cause of cancer deaths globally in women (Jemal et al., 2011). Therefore, 
extensive research has been done to explore treatment options for this disease.  Moreover, 
it is estimated that1 in 9 women will develop breast cancer at some point in her lifetime 
and that 1 in 30 will die of it (The Breast Cancer Foundation, 2014). Importantly, breast 
cell division is stimulated by estrogen that can increase chances of developing breast 
cancer because of the high level of estrogen production in women’s bodies (Hilakivi-
Clarke et al., 2001). 
1.3. Types of breast cancer  
Each breast is made up of 15 to 20 glands called lobes, which have small 
structures called lobules. These lobes are connected to the nipple by tiny canals called 
ducts. The rest of the breast is fat. Breast cancer starts in the tissues of the breast which 
can extend up to the collarbone and from the armpit to the breastbone. Breast cancers are 
classified depending on which breast tissues develop the tumours. Ductal carcinoma 
arises from epithelial cells in the milk ducts tubes that carry breast milk to the nipple and 
can metastasize to surrounding tissues. It is the most common histological form of breast 
cancer (Albrektsen et al., 2010) and represents roughly 85% of all invasive breast 
cancers. Lobular carcinoma arises from epithelial cells in milk glands where the milk is 
produced and can also spread to other parts of the body. It accounts for around 15% of all 
invasive breast cancer cases (Reed et al., 2015).  
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Invasive ductal and lobular carcinomas refer to breast cancer where the breast 
cells can metastasize over time to the lymph nodes and other areas of the body through 
the bloodstream or lymphatic system. On the other hand, in situ ductal and lobular breast 
cancers don’t have the ability to invade beyond their original location (Harold et al., 
1998). Due to this reason, in situ ductal carcinoma is considered an early stage of breast 
cancer so treatment will be effectively for most women. However, it requires treatment 
because even though it is not life-threatening it increases the risk of developing into an 
invasive breast cancer. Recently, the rate of women who are diagnosed with DCIS has 
increased dramatically because of widespread screening with mammograms (Lenavo et 
al., 2014). However, in situ lobular cancer is not a true malignant cancer but is an 
indicator that a female is at a high risk to develop invasive cancer later in life.  
There are also other rare types of invasive breast cancer beside these common 
types of invasive cancer such medullary, tabular, mucinous, etc. (Winer et al., 2001). 
Medullary carcinoma accounts for 5% of all cases of invasive breast cancer and are more 
common in women in their late 40s and 50s. Mucinous carcinoma represents less than 
2% of all breast cancers (Zhang et al., 2014) and it tends to be less aggressive than other 
type of invasive carcinoma (Schneider et al., 2011).  Tabular carcinoma is an uncommon 
type of breast carcinoma (Romano et al., 2015). It makes up about 1% to 4% of all breast 
cancer and usually grows slowly (Rakha et al., 2009).  
1.4. Risk factors for breast cancer 
There are several risk factors that promote the chances to develop breast cancer. 
Every woman is at risk of developing a breast cancer in her lifetime. Breast cancer is a 
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complex disease that results from multiple environmental and hereditary risk factors 
(Perera, 1997). Genetic factors are thought to be a relatively weak contributor to breast 
cancer (Venitt, 1994) and accounts for about 5% to 10% of all breast cancer risk (Perera, 
1997). However, environment factors are highly associated with an increased risk of 
breast cancer incidences (Strumylaitė et al., 2009). There are several environmental 
conditions that play more important roles in the growing incidence of breast cancer, 
which can be classified as modifiable risk factors and non-modifiable factors (Petracci et 
al., 2011). The modifiable risk factors include body weight, alcohol consumption, 
radiation exposure, smoking, physical activity, and hormone replacement therapy. The 
non-modifiable risk factors are female gender, advanced age, an early menarche, late 
menopause, breast density, and family history.  
1.4.1. Non-modifiable risk factors 
Although men can be diagnosed with breast cancer, the risk of developing the 
disease is 100 times more likely for a female (Meister et al., 2002). Women have 
significantly higher breast cancer incidences because they have more breast tissue than 
men. 
The rates of breast cancer incidence clearly increase with age (McPherson et al., 
2000).  For every 10 years of age, the incidence of breast cancer doubles for women 
before menopause.  Women with early menarche (12 years or younger) and late 
menopause (55 years or older) are at significantly higher risk of developing breast cancer. 
Early menarche is associated with early onset of regular menstrual cycles that increases 
the hormone exposure that associates with ovulatory cycles. Moreover, women with 
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menarche prior to 12 years of age produce relatively high estrogen concentrations 
compared to those starting menarche later (Kelsey et al., 1993). Women who first 
menstruated at age 15 had a 23% lower risk of breast cancer than those who start 
menarche at age 12 or younger (Brinton et al., 1988). 
Mammograms measure the proportion of fat (which has low density) and the 
presence of areas of high cell concentration in the breast. Breast density is related to age 
with an estimated 50% of women of age between 40-49 and 30% of women aged 70 or 
more shown to have dense breast tissue (50 %) (Harvey and Bovberg, 2004). A dense 
breast has the potential to be use as a predictor of breast cancer risk especially in older 
women (McCormack and dos Santos Silva, 2006). The increasing ratio of developing 
breast cancer is a four to six fold (White, 2000) for women with 75% dense breast 
(Bolan, 2013). In addition, the risk percentage of breast cancer attributable to any dens 
breast is 40% (Harvey and Bovberg, 2004). 
1.4.2. Family history of cancer 
  Risk associated with family history of breast cancer varies depends on the 
number of affected family members, the age of the family member at diagnosis, and the 
degree of relatedness. A single case of breast cancer among first-degree relative, 
increases the risk of developing cancer up to two–to threefold (Hulka et al., 2001).  This 
indicates that the individual risk among women with a family history of breast cancer is 
higher than their age-associated risk. However, the vast majority of women who get 
breast cancer have no such family history of the disease.  
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However, family history is a key of risk factor in women that develop invasive 
breast cancer and this risk is highly increased when first-degree relative have developed 
breast cancer before the age of 50 years, bilateral breast cancer, ovarian cancer or male 
relatives with breast cancer (Warner et al., 2011). It provides clues as to hereditary breast 
cancer, which accounts for approximately 7% of overall breast cancer risk (Hulka et al., 
2001). Importantly, about 20% to 25% of the excess familial risk is contributed by the 
genetic factors that are known to be associated with mutations in the BRCA1 and BRCA2 
genes (Lalloo and Evans, 2012). 
BRCA1 and BRCA2 are high-penetrance breast cancer susceptibility genes and it 
is well known as their mutations confer a high risk of hereditary breast cancer (Afonso, 
2009).  These genes are highly associated with developing breast cancer at both early and 
later age. Therefore, a mutated BRCA1 dramatically increases the average risk of breast 
cancer risk by age of 70 to between 55% and 85%, while the average range is between 
37% and 85% for BRCA2 mutations (Afonso, 2009). However, it is estimated that about 
55–70% of individuals who do not have family risk but carry mutation in BRCA1 are at 
high risk of developing breast cancer (Lalloo and Evans, 2012). In contrast, the likelihood 
for women with no family history and without the BRCA1 or 2-gene mutations is 12% 
(Antoniou et al., 2003).  
BRCA1, which plays a critical role in genomic stability, was identified in 1990 
and appears to be linked to breast cancer and ovarian cancer (National Center for 
Biotechnology Information, 1998). BRCA2 appears to be linked to male breast cancer 
(National Center for Biotechnology Information, 1998).  These two human genes produce 
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tumour suppressor proteins that repair damaged DNA or destroy cells when DNA cannot 
be repaired. When one of these genes is altered, the protein will not function properly and 
DNA damage may not be repaired properly, which can generate cancer-causing 
mutations. 
Furthermore, harmful mutations in both genes raise the chances of developing 
different types of cancers in addition to breast and ovarian cancer, such as prostate cancer 
for men (Levy-Lahad et al., 2007) and pancreatic cancer for both genders (Ferrone et al., 
2009). 
1.4.3. Modifiable risk factors for breast cancer  
Many studies have suggested that a high level exposure to ionizing radiation or 
repeated chest fluoroscopies or examination by x-ray can induce breast cancer. The risk 
of developing cancer varies according to dose of exposure, age of exposure, and time 
after exposure (Land et al., 1980).  Females between 10 and 20 years are at greater risk of 
developing breast cancer following radiation exposure as the breast tissue is rapidly 
developing and responds significantly to the maximum effects of radiation. Additionally, 
this risk is highly increased during adolescence and remains high for 10 to 15 years after 
the initial exposure (Singletary, 2003). Therefore, this risk decreases by age 30 (Kelsey et 
al., 1998). This association has been derived from studies of both atomic bomb survivors 
and women who received radiation therapy (Singletary, 2003).  
Breast cancer incidence appears to rise during the use of hormonal replacement 
therapy (HRT). Although HRT, which involves treatment with estrogen with or without 
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progestin, has been used to relieve menopausal symptoms and prevent osteoporosis, the 
risk of breast cancer was found to be relatively increased by 2.3% for every year of use 
by women without breast cancer (Colditz, 1998). Importantly, the National Institutes of 
Health and Epidemiologic Studies have shown that recent use of HRT was associated 
with a greater risk of breast cancer than for those who stopped this treatment for a long 
period of time (Singletary, 2003). 
Multiple studies indicate that moderate alcohol intake has no significant effect on 
breast cancer incidence rates (Singletary, 2003; Longnecker, et al., 1988). However, 
numerous epidemiologic studies support a positive but not strong association between 
alcohol consumption and breast cancer (Longnecker et al., 1988; Zhang, et al., 2007). A 
meta-analysis of 53 epidemiologic studies showed that a comparison of drinkers who 
drink more than 45 grams of alcohol daily versus non-drinkers revealed 1.5 times more 
risk of developing breast cancer (Hamajima et al., 2002). 
1.5. Tumor receptors 
There are three major function tumour receptors, which can be used to indicate 
cancer status and which play a critical role in tumour development and progression 
(Mankoff et al., 2008). These receptors are the estrogen receptor (ER), progesterone 
receptor (PR), and human epidermal growth factor receptor 2 (HER2) (Cadoo et al., 
2013).  Additionally, these receptors have been used for diagnosis, classification of breast 
cancer subtypes, and tumour specific therapy. 
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Overexpression of hormone receptors is related with neoplastic proliferation for 
some tumour types including breast cancer (Huber et al., 2009). Most breast tumours 
express ER hormone receptor, which accounts for 75% of all invasive breast cancer 
followed by PR, which accounts for 65% of breast cancers. Both ER and PR receptors are 
the targets for endocrine therapy such as tamoxifen treatment. On the other hand, HER-2 
expression accounts for 15-20% of all invasive breast cancers. HER2- positive expression 
in tumours tends to indicate more aggressive tumours that are more responsive to drug 
treatment (Marty et al., 2005). Triple negative breast cancer is characterized as estrogen 
receptor-negative; progestin receptor-negative and human epidermal grow factor 
receptor-negative (Hudis, 2011).  It represents 10-20% of all invasive breast tumours 
(Schwentner et al., 2013). This type of tumour does not respond to hormone therapy, or 
to chemical therapy. Thus, it is typically treated with combinational treatment and still 
has a poor prognosis. 
1.6. Treatment of breast cancer 
Breast cancer is a heterogeneous disease that becomes a target for several 
treatments divided into local and systemic therapies, according to the breast cancer types, 
stages, and sites of the tumour as well as other patient-related factors such as age and 
general health. Local treatment options include surgery and radiotherapy that are applied 
to specific areas of the body. Systemic treatments involve the entire body, where the 
tumour has spread and includes chemotherapy, hormonal therapy, and HER2-targeted 
therapies. Usually, the best results are obtained when two or more methods are used in 
combination (Verma et al., 2004).  
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1.6.1. Surgery 
In the early stage of breast cancer, surgery is the first treatment (Early Breast 
Cancer Trialist’s Collaborative Group, 2006). Usually, such early disease is detected in 
breast only or in regional lymph nodes and can be removed surgically. Additionally, it 
can be diagnosed by screening mammography and treated with just local treatments 
(Hortobagyi, 1998). The aim of surgery is basically to remove all tumour tissues and 
nearby margins to reduce the local recurrence. However, there are two options of surgery, 
mastectomy or breast-conserving surgery, followed by radiation with some factors to 
guide the decision including tumour size, location, cosmetic achievement post-surgery, 
and pre-exposure to radiation (Gabriel and Domchek, 2010).  
Mastectomy includes removal of the entire breast tissue and chest wall tissue with 
axillary lymph nodes (Kaviani et al., 2013). Traditionally, it is used when local 
recurrence risk is increased and is associated with a size more than 5 cm3, existence of 
four or more positive lymph nodes and occurrence of vascular invasion (Kaviani et al., 
2013).  Even after mastectomy, the risk of local recurrence can continue and it can be 
reduced by post-mastectomy radiotherapy which causes a reduction in long term breast 
mortality although some studies have shown that post-mastectomy radiotherapy may only 
have a slight effect within the first few years on breast cancer death. Therefore, it is 
suggested to treat patients at high risk of local reoccurrence with radiotherapy after 
mastectomy (Siegel et al., 2012).  
Breast conservation therapy (BCT) removes the cancerous lump with a portion of 
the breast tissue surrounding the cancerous lump without increasing the chance of local 
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recurrence (Gabriel and Domchek, 2010). Additionally, the lymph nodes under the arm 
might be removed if the cancer has spread (Kroman et al., 2004).  However, the breast 
itself remains relatively undamaged. The National Institutes of Health recommended 
BCT with radiation in 1990 as an appropriate treatment for the most women with early-
stage breast cancer (Lee et al., 2009). This recommendation was made after early-
randomized trials showed that there was no statistically significant difference in survival 
rate and local recurrence between patients treated with BCT and those undergoing a 
mastectomy (Early Breast Cancer Trialists Group et al., 2011). 
Currently, around 60% of patients with early-stage breast tumour are treated with 
BCT (Early Breast Cancer Trialists Group et al., 2011). According to some studies young 
women experience local recurrence more frequently than middle-old women following 
BCT (Kroman, et al., 2004; Harrold et al., 1998). Women aged 35 years or less at 
diagnosis that receive BCT represent more than 30% of 10-year local recurrence rates 
while middle-aged and older women represent less than 10% of 10-year local recurrence 
rates (Kroman et al., 2004). However, in two big randomized trials analysis, results found 
that young women treated with mastectomy did not show a rise in local recurrence 
compared to old patients (Gabriel, 1998).  These studies display that the disease-free 
survival rate from breast cancer is the same for patients undergoing mastectomy or 
undergoing BCT along with radiotherapy particularly in women with early stage Breast 
cancer  (Stages I and II) (Kaviani et al., 2013).   
Numerous publications have analyzed the risk of local recurrence associated with 
early stage of breast cancer. In mastectomized patients, local recurrence to the chest wall 
accounts for 2-10%, whereas local recurrence is 3-10% after BCT (Kaviani et al., 2013). 
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The vast majority of women with local recurrence after BCT can be recovered with 
mastectomy and further recurrence after mastectomy is about 5%.  
1.6.2. Radiotherapy 
Radiotherapy is one of the local treatment methods that destroy the tumours by 
targeting the DNA of the cancer cells. Moreover, it is usually given to younger patients 
after BCT and following mastectomy for patients with a greater risk of local recurrence 
(Early Breast Cancer Trialists Group et al., 2011). Results from the Oxford overview 
analysis indicated that the 5-year local recurrence risk rate for patients treated with post-
surgery with radiotherapy was 7%. This proportion is significantly increased to 26% in 
women undergoing breast-conserving surgery only. Moreover, the 15-year breast cancer 
mortality rate in patients who underwent radiotherapy following surgery was 30.5% 
whereas for women treated with surgery alone the mortality rate was raised to 35.9% 
(Ring et al., 2011). Additionally, the incidences of local and regional recurrences were 
reduced by 50-to75% after post mastectomy radiotherapy, but according to a meta- 
analysis of several trials this decrease was not accompanied by increased survival 
(Gabriel and Domchek, 2010). For that reason, radiotherapy after mastectomy is 
suggested only for women at great risk for local or regional recurrence (patients with lots 
of positive axillary lymph nodes and those with large tumours invading the chest wall or 
the skin of the breast). However, recent randomized trial indicated that overall long-term 
survival rate in patients treated with chemotherapy before radiotherapy was significantly 
effective (Gabriel and Domchek, 2010). 
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1.6.3. Chemotherapy 
Chemotherapy usually includes cytotoxic drugs, which can either directly kill 
cancer cells or inhibit tumour cell proliferation. For adjuvant therapy, which is usually 
given after surgery, combination chemotherapy is more successful than single-drug 
therapy as it reduces the risk of mortality by about 20% annually (Gabriel et al., 1998). 
One of the early combination protocols with proven efficacy was composed of 
cyclophosphamide, methotrexate and 5-fluorouracil (CMF) (Bonadonna et al., 1995). The 
use of anthracyclines in chemotherapy protocols is now used extensively in the treatment 
of breast cancer (Crozier et al., 2014).  
Anthracyclines appear to act by inducing covalent topoisomerase II – DNA 
complexes that result in single or double strand DNA breaks. Anthracyclines, such as 
doxorubicin and epirubicin, are used in adjuvant and neoadjuvant chemotherapy and are 
the frequently preferred primary line of chemotherapeutic treatment for locally advanced 
breast cancer (Bonadonna et al., 1995).  According to the Early Breast Cancer Trialists’ 
Collaborative Group (2005) poly-chemotherapy acts to decrease disease associated with 
increasing age, showing a decrease in mortality of 30, 15, 9 and 13% for the age groups 
40–49, 50–59, 60–69 and 70 and older, respectively (Ring et al., 2011). Additionally, age 
was found to be associated with chemotherapy related deaths: 0.2% for age 50, 0.7% for 
ages (51-64), and 1.5% for those over age 65 (Ring et al., 2011).   
1.6.4. Hormone therapy 
Hormone therapy is another systemic therapy used beside chemotherapy to treat 
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patients with breast cancer. Hormone therapy uses drugs that block hormone binding and 
deprives the tumour cells of hormone. Since many breast cancer cells grow faster and 
spread more in the presence of female sex hormones blocking hormone binding results in 
inhibition of tumour cell regrowth (Liedtke and Kiesel, 2012). Hormonal therapy is 
confirmed to greatly reduce the risk of recurrence and mortality. Currently, hormone 
receptor positive breast cancers make up around 75% to 80% of the diagnosed breast 
cancers (Cadoo et al., 2013).  
Tamoxifen is the most commonly used antagonist and is an effective treatment for 
estrogen receptor (ER) positive breast cancers. Tamoxifen has been shown to 
significantly reduce the risks of recurrence for breast cancer for all age groups (Gabriel et 
al., 1998) and decreases the breast cancer death rate in hormone receptor-positive breast 
cancer patients by up to one third (Shiavon and Smith, 2014).  Patients who take 
tamoxifen for around 5 years have a decrease in annual recurrence of 47% and a decrease 
in mortality of 26% (Early Breast Cancer Trialists’ Collaborative Group, 1998)  
Importantly, only women with ER-positive tumours can benefit from tamoxifen 
while patients with ER-negative tumours appear to show no benefits from tamoxifen 
(Gabriel et al., 1998).  
1.6.5. Side effects of chemotherapy treatments  
Attempts to cure breast cancer by using a variety of treatments that destroy 
tumour cells can also affect healthy cells. Therefore, chemotherapy has potential benefits 
and also possible risks. The various side effects associated with chemotherapy are 
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divided into short and long term. Long-term side effects involve issues of treatment 
occurring after the conclusion of chemotherapy while short-term side effects include 
those toxic effects occurring during treatment. Short term side effects include depression, 
nausea, vomiting, decreased muscular strength, weakness, fatigue, decreased aerobic 
capacity, cardiac dysfunction, and weight gain (Partridge et al., 2001). However, the 
negative side effects of breast cancer treatment have increased attention on the need to 
develop more effective agents that can prevent and treat metastasis of breast cancer with 
minimum side risks and less painful therapy such treatments derived from natural 
medicine.  
1.7. Natural products and cancer 
Different breast cancer treatments have limited options of drug combinations. 
Consequently, there is a growing need to discover new methods that effectively 
management breast cancer with less toxic effects (Nabavi et al., 2015).  Most 
chemotherapy drugs have nonselective toxic effects on normal tissues leading to 
neutropenia (a decrease in the number of neutrophils) the most commonly observed 
adverse reaction, which raises the chances of infections (Santos Arujo et al., 2012).  
Natural products provide a diversity of potential anticancer compounds that can 
be used for inhibition of breast cancer cells or prevention of breast cancer. Additionally, 
the World Health Organization (WHO) has estimated that 80% of the population 
consume traditional medicine as an alternative treatment for their diseases and most of 
these medicines involve plant-derived medicine and their active components (Nabavi et 
al., 2015; Krishnaiah et al., 2011).  
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Natural products (NP) are described as chemical substances or groups of 
substances, produced by a living organism that has pharmacological activities that are 
used without chemical modification (Gollahon et al., 2011). Natural products also play a 
highly significant role in cancer treatment  (Newman et al., 2003) since several natural 
products can work to decrease the side effects of therapy while improving survival (Kado 
et al., 2012). Treatment with natural products may have some benefits over treatment 
with other cancer treatment and may provide lower charge selections. 
  Under stress, human bodies produce more reactive oxygen species than 
antioxidants and this imbalance can cause many health problems. As result, consuming 
health products is high among patients with chronic health problem since natural products 
contain many antioxidants that can quench the reactive free radicals (Krishnaiah et al., 
2011). Today, extensive numbers of anticancer agents are natural products or are derived 
from natural products and play a relevant role in cancer treatment (Nobili et al., 2009).  
1.8. Uncaria tomentosa  
Uncaria tomentosa is one of the herbal medicines that is widely used for 
treatment of several diseases such as gastric illnesses, cancer, viral infections, arthritis 
and other inflammatory disorders (Aguilar et al., 2002; Goncalves et al., 2005).  
Uncaria tomentosa, which is also known as cat’s claw, grows in the Amazon 
forests of Peru. It is a large woody vine from the Rubiaceae family and Cinchonoideae 
subfamily. It is traditionally used as a therapy for different disorders such as respiratory 
infections, diabetes, gastrointestinal disorders, gastritis, and rheumatoid arthritis 
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(Heitzman et al., 2005).  The Peruvian population has used Uncaria tomentosa for 
centuries as treatment for several diseases (Ccahuana et al., 2007).  Currently, several 
nutritional formulations contain Uncaria tomentosa to treat a variety of health issues 
(Sheng et al., 2005). 
The root bark of cat’s claw contains secondary metabolites such as polyphenols, 
oxindole alkaloids, and quinovic acid glycosides (Aguilar et al., 2002). Additionally, bark 
extracts have been traditionally used for their anticancer and anti-inflammatory 
prosperities.  
Uncaria tomentosa extracts have antibacterial, immunostimulating, antiviral, 
antirheumatic, and anti-oxidative and anticancer effects  (De Martino et al., 2006; Bors et 
al., 2012). Uncaria tomentosa’ constituents have also showed cytotoxic effects on breast 
cancer cells (Bacher et al., 2006).  
Treatment of cancer cells with Uncaria tomentosa causes inhibition of TNFα 
production and nuclear transcription factor NF-κB (Akesson et al., 2003). Moreover, 
several studies have reported that Uncaria tomentosa has anti-proliferative effects on 
different cell lines (De Martino et al., 2006).  Sheng et al (2005) reported that an aqueous 
extract of Uncaria tomentosa causes cell growth inhibition without cell death which 
increase the opportunities for DNA repair leading to anti-inflammatory activity, cancer 
prevention, and immune stimulation (De Martino et al., 2006).  A water extract of 
Uncaria tomentosa decreased proliferation of normal mouse T and B-lymphocytes and 
this reduction was not because of apoptosis or toxicity (Akesson et al., 2003). 
Sheng et al (1998; 2000) also stated that a water extract of Uncaria tomentosa 
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decreases tumour cell division in vitro and induces apoptosis, which was confirmed by 
DNA fragmentation and morphological changes (De Martino et al., 2006). A clinical trial 
demonstrated that breast cancer patients who take Uncaria tomentosa along with 
traditional cancer therapies have fewer side effects than those who were just treated with 
chemotherapy or radiation (Araújo et al., 2012). Moreover, extracts of Uncaria 
tomentosa have been show to promote DNA repair and prevent mutation and cell damage 
in breast cancer patients  (Araújo et al., 2012). Uncaria tomentosa treatment minimizes 
the neutropenia resulting from chemotherapy and was effective as an adjuvant treatment 
for breast cancer (Araújo et al., 2012).   
1.9. Apoptosis  
Apoptosis, necrosis, and autophagy are the most common classes of cell death 
that can be catalyzed according to the cell’s morphological appearance (Kroemer et al., 
2009).  Necrosis, in contrast to apoptosis, is a passive form of cell death. It is initiated by 
environmental distresses and results in uncontrolled release of inflammatory cellular 
contents (Fink and Cookson, 2005; Edinger and Thompson, 2004). Necrosis is 
characterized morphologically by the breakdown of the plasma membrane, increased cell 
volume and the presence of inflammation around the dying cells (Edinger and Thompson, 
2004). 
The first appearance of apoptosis in the biomedical literature was in 1972 (Wyllie, 
1997). It is one of the essential biochemical processes and is responsible for eliminating 
damaged cells and controlling cell division (Sheng et al., 2005).   Apoptosis is a process 
of programmed cell death that is a main component of various processes and that plays an 
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important role in different physiological processes in adult tissues including the function 
and development of the immune system, chemically-induced cell death, normal cell 
turnover, and during embryonic development (Reed, 2000; Elmore, 2007). It also occurs 
during aging to maintain a stable cell population. 
Apoptosis is a physiological process of cellular suicide and is characterized by 
morphological phenomenon including plasma membrane blebbing, chromatin 
condensation, cell shrinking, and cellular fragmentation (Elmore et al., 2007). Eventually, 
the morphological features of apoptosis includes: cell shrinking and separation from its 
neighbours; the nucleus starts to break apart, and the DNA cleaves into inter-nucleosomal 
fragments; then the cell fragments into several apoptotic bodies each with surrounding 
membrane and extensive plasma membrane blebbing; and, the apoptotic bodies are 
cleared by phagocytic cells which secret cytokines to inhibit inflammation around the 
dying cells (Edinger and Thompson, 2004; Reed, 2000; Wyllie, 1997  
The extrinsic (death receptor) and intrinsic (mitochondrial) pathways represent 
the two main distinct subtypes of apoptosis. These two pathways can induce apoptosis 
through diverse biochemical routes although the results are morphologically similar 
(Edinger and Thompson, 2004; Elmore, 2007).  
The extrinsic pathway is mediated by ligation of death receptors on the plasma 
membrane with ligands leading to activation of caspase 8, which directly activates 
caspase 3 and 7 causing apoptosis.  The intrinsic pathway is activated by permeablization 
of the mitochondrial outer membrane by Bcl-2 family members that results in the release 
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of cytochrome C that activates caspase 9 and 3 to cause apoptosis (Elmore 2007; Tait et 
al., 2010).  
1.10. Uncaria tomentosa induces apoptosis 
Phytochemical studies of Uncaria tomentosa have identified three main fractions 
of chemicals secondary metabolism that have antitumor effects; the polyphenols, 
alkaloids and triterpene derivatives (Dietrich et al., 2014). In addition, some studies have 
shown that the inhibitory effects of Uncaria tomentosa on the proliferation of different 
cancer cell lines, such as breast cancer, cervical carcinoma and osteosarcoma, are 
mediated through caspase-dependent apoptosis (Dietrich et al., 2014).  
C-Med-100 is a novel water extract of Uncaria tomentosa that can inhibit the in 
vitro growth of K562 and HL60 (human leukemia cell lines) cancer cells and human 
EBV-transformed B lymphoma cell lines through the induction of apoptosis confirmed 
by inter-nucleosomal DNA fragmentation and characteristic morphological changes 
(Sheng et al., 1997).  
De Martino et al (2006) examined the apoptotic effect of Uncaria tomentosa bark 
extracts on three tumour cell lines, MCF7 (breast cancer), HeLa (human cervical 
carcinoma cell line) and SAOS (human osteosarcoma cell line). The results provided 
evidence that treatment with the n-BuOH- soluble fraction of the water extracts of 
Uncaria tomentosa were able to induce apoptosis through activation of caspase 3 in a 
dose –dependent manner (De Martino et al., 2006).  
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1.11. Apoptosis and chemotherapy 
Several types of chemotherapy increase cellular stress resulting in the induction of 
apoptosis (Fulda et al., 2010). Many reports have suggested that chemotherapy induced 
apoptosis involves increased expression of death receptor ligands, particularly the Fas 
ligand. Other reports have shown that chemotherapy causes apoptosis by stimulating 
release of cytochrome C from mitochondria (Kaufmann and Earnshaw, 2000).  
Fas ligation causes activation of cell death caspases.  This initiates a proteolytic 
cascade that leads to the cellular fragmentation and death (Crowe and Yoon, 2002).  
The cytotoxic effects of chemotherapy induce DNA damage, which in turn 
activates P53.  Activation of P53 is result in induction of apoptosis by both intrinsic and 
extrinsic singling pathways (Seitz et al., 2010).   
1.12. Thesis objectives 
Previous studies have shown that treatment with extracts of Uncaria tomentosa 
was able to inhibit growth of some cancer cells. However, it was not clear if treatment 
with Uncaria tomentosa was active against human breast cancer cells or if was able to 
preferentially kill cancer cells compared to non-malignant cells. This study was 
performed to examine the effects of Ucaria tomentosa extracts (alcoholic versus 
Phosphate-buffered saline extracts) on the proliferation of malignant breast cell lines 
(MCF7 and MDA-MB-231) and non-malignant cell lines (HBL-100, HSG, and 
HEK293). In addition, studies were designed to identify the mechanisms by which 
Uncaria tomentosa causes inhibition of MCF7 cell growth or increases in cell death and 
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to determine if Uncaria tomentosa has potential as a treatment for patients with breast 
cancer. 
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Chapter 2. Materials and Methods  
2.1. Tissue culture  
The MCF7 (human ER-positive breast cancer), MDA-MB-231 (human triple 
negative breast cancer), HBL 100 (human breast), HEK293T (human embryonic kidney) 
and HSG (human salivary gland) cell lines were purchased from the American Type 
Culture Collection (Manassas, VA). All of these cells were cultured in Dulbecco’s 
Modified Essential Medium (DMEM, Hyclone, Logan, UT) supplemented with 10% fetal 
bovine serum (Hyclone), 100 μg/ml streptomycin, and 100μ/ml penicillin (Invitroogen, 
Burlington, ON). Cells were incubated in a humidified atmosphere in a 5% CO2 
incubator at 37°C. 
2.2. Drug preparation  
Uncaria tomentosa was purchased as Natural Health Product NHP (Cat's Claw 
extract, Now Foods, Bloomington, IL. Code 84618) or obtained as a dried powder 
prepared from the bark of the plant by Rosa Rosales (Lima, Peru). For the preparation of 
ethanol extracts, 1g of Uncaria tomentosa powder was dissolved in 10 ml of 70% ethanol 
and boiled for 60 minutes. For preparation of PBS extracts, 1g of Uncaria tomentosa was 
suspended in 9 ml of water and 1ml of 10X PBS stock and then boiled for 60 min. Both 
suspensions were centrifuged for at 800xg for 10 min to remove the insoluble material. 
The supernatant was then filtered through 0.22 μM syringe filters and stored in aliquots at 
-80 °C 
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2. 3. Cell Treatments  
The MCF7, MDA-MB-231, HBL 100, HEK293T, and HSG cells, maintained in 
Dulbecco’s modified Eagle’s medium (DMEM), were harvested using trypsin (0.25 
ug/ml, Life Technologies) and resuspended in culture media at 2x104 cells/ml.  The cells 
were plated on a 5x96 well plates; 100 μl of cell suspension (2000 cells/well) were added 
to each well. The cells were then incubated in a 5% CO2 incubator at 37°C. On day 1, the 
cells were treated with the Uncaria tomentosa extracts and maintained for the duration of 
the experiment without a media change. The cells were treated with different 
concentrations of both the ethanolic and PBS extracts (0.05, 0.1, 0.25, 0.5, and 1%), as 
indicated with a media-only negative control.  On each day, for 5 days, the relative cell 
number was determined using the MTT assay.  
2.4. MTT assay (Methyl Tetrazolium Blue)  
The antiproliferative effects of Uncaria tomentosa were measured by determining 
changes in cell viability using the MTT assay. The MTT assay is based on the ability of 
living cells to convert a yellow MTT solution into an insoluble formazan purple salt in 
the cell cytoplasm. Thus, color formation serves as convenient marker only the viable 
cells. Malignant cells (MCF7, MDA-MB-231) and non-malignant cells (HBL-100, HEK 
293T, and HSG) for cultured on 96 well plates were treated with various concentrations 
of Uncaria tomentosa extracts and cell viability measured each day for five days. Each 
day, 10 μl/ml of 0.4 μg/ml MTT in PBS, pH 7.4, was added to each well and incubated 
for 4 hr. Following the incubation, the media was removed and 100 μl of dimethyl 
sulfoxide (DMSO) was pipetted into each well to dissolve the formazan crystals into 
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solution. The absorbance was measured at 540 nm using a plate reader (SpectraMax 340 
PC 389) and the relative absorbance reported for each treatment condition. 
2.5. Cell Morphology  
The MCF7, MDA-MB-231, HBL 100 (human breast), HEK293T and HSG cells 
were cultured in 35 mm2 culture plates and incubated overnight at 37°C. The cells were 
then treated with suspending media (negative control), a low dose (0.01%) or a high dose 
(1%) of either the alcoholic or PBS extracts of Uncaria tomentosa. The morphological 
change in the cells was imaged daily for 5 days using an Inverted Phase Contrast 
Axiovert 100 Microscope (Zeiss Microscopes) and recorded using Northern Eclipse 
Software. 
2.6. Wound healing migration assay  
The MCF7 cells were plated on 6 well plates and incubated for (24) hours to 
allow formation of a confluent cell monolayer. Then, the monolayer was gently scratched 
with a 200-μl plastic pipet tip to create a “wound” of cleared cells.  The cells were then 
treated with suspending media (control) or with the high dose of either the alcoholic or 
PBS extracts of Uncaria tomentosa extracts (1%). Digital images were documented each 
day after treatment using an Axiovert 100 microscope and Northern Eclipse software and 
the diameter of the gap measured.  The changes in the gap were plotted for each day to 
determine the effect of treatment on “wound healing”. 
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2.7. Cell Staining assay (Acridine Orange/Ethidium Bromide)  
This experiment was performed to visualize any nuclear changes associated with 
apoptosis in response to treatment with Uncaria tomentosa extracts The MCF-7 cells 
were plated on sterile glass coverslips in 6- well plates in DMEM culture media and 
incubated overnight at 37°C. The cells were treated with suspending media or the high 
dose of Uncaria tomentosa ethanol or PBS extracts (1%) for different time points (24, 48, 
and 72 h). Cells were treated with 6 μg/ml of camptothecin for 24 as a positive control for 
apoptosis. The cells were then stained with 10 ug/ml of acridine orange (Sigma-Aldrich) 
and 10 ug/ml of ethidium bromide (Sigma- Aldrich) for 15 minutes. The coverslips were 
washed with PBS and gently mounted onto glass slides in 80% glycerol in PBS.  The 
fluorescently labelled cells were visualized on an LSM 510 fluorescence microscope 
(Zeiss) and images obtained showing acridine orange (green), ethidium bromide (red), 
and phase contrast fields. 
2.8. TUNEL assay (terminal deoxynucleotidyl transferase dUTP nick 
end labeling)  
DNA fragmentation due to apoptosis was detected using a TUNEL assay 
according to the manufacturer’s instructions (Roche, Laval, QB). MCF7 cells were grown 
on sterile glass cover slips in DMEM culture media and incubated overnight at 37°C. 
Cells were treated with suspending media or with media containing 1% Uncaria 
tomentosa ethanolic or PBS extracts and incubated for three different time points (24hrs, 
48hrs and 72hrs). Cells were treated with 6 μg/ml of camptothecin for 24 h and used as a 
positive control for apoptosis. After treatment, the cells were fixed by incubation in 1ml 
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of 4% freshly prepared formaldehyde for 5 minutes at 4°C. The fixative was removed and 
the cells were rinsed with PBS and then permeabilized by incubation in 1% Triton X- 100 
in PBS at 4°C for 3 minutes. The cells were rewashed twice with PBS. The cells were 
then treated with 50 μl of the Tunel reaction mixture and incubated for 60 minutes at 
37oC. The stained coverslips were rinsed in PBS, pH 7.4, twice and then mounted on 
glass slides. The slides were directly viewed using an LSM 510 fluorescence microscope 
and images of the fluorescent label (green) and phase contrast images obtained. 
2.9. Caspase activity assay (caspase colorimetric protease sampler kit)  
The Caspase activity assay (Life Technology) was used to detect the activity of 
caspases-3, -8, and -9 in apoptotic cells. MCF7 cells were plated on 150x20 cm plates. 
Duplicate cell plates were set up for each concentration. Cells were treated with low dose 
(0.01%) and high dose of ethanol extract of (1%) for 72 hours. 1% of only ethanol was 
used as negative control for apoptosis. The cells were harvested and 50 μl of chilled Cell 
Lysis Buffer (provided in the kit) were added to 3-5 x 10
6 
cells/sample and then 
incubated for 10 minutes on ice.   The cell lysates were centrifuged for 1 minute at 
10,000-x g and the supernatants transferred to new tubes and placed on ice. Protein 
concentration was detection using a BCA assay and the sample diluted to a concentration 
of 50-200 μg protein per 50 μl Cell Lysis Buffer (1- 4 mg/mL). 50 μl of 2x Reaction 
Buffer/DTT mix (provided in the kit) was added to each sample and 5 μl of the 4 mM 
colorimetric substrate (200 μM final concentration) was added.  Samples were incubated 
at 37 °C for 2 hours and the absorbance read on a (SpectraMax 340 PC 389) at 405 nm. 
The increase in caspases -3, -8, -9 activity were measured by comparison with an un-
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induced control.  
2.10. Statistical analysis 
The cell viability data were expressed as mean ± standard deviation of three 
separate experiments and were analyzed using Graph Pad Prism program and significant 
differences confirmed by ANOVA * (P < 0.05).  Post-hoc analysis for differences 
between treatments was done using Tukey tests.  The caspase assay tests were done in 
triplicate, each experiment normalized (controls set to 1), and the average and standard 
deviation for each assay reported.  The difference between groups was assessed using a 
Students t-test. 
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 Chapter 3. Results  
3.1. Cell proliferative assay   
The MTT assay was used for in vitro experiments to determine the effects of 
treatment with Uncaria tomentosa extracts on the viability of malignant cell lines (MCF7 
and MDA-MB-231 cells), and non-malignant cell lines (HBL100, HEK 239T, and HSG 
cells). Treatment with a high dose (1%) of 70% ethanol extract of Uncaria tomentosa 
significantly inhibited cell growth of MCF7 cells by ~65% (Figure 3.1) and of MDA-
MB-231 by ~35%  (Figure 3.3) (p<0.05) particularly at day 3 compared to the low 
concentration (0.05%), which showed only a slight decrease in cell proliferation 
compared to the untreated control cells. There was a small level of inhibition in MCF7 
cell growth (30%) after treatment with high dose (1%) of PBS extracts of Uncaria 
tomentosa (p<0.05) (Figure 3.2) compared to the low concentration, which did not affect 
the proliferation of the cells compared to the untreated control cells.  Treatment of MDA-
MB-231 cells with the PBS extract of Uncaria tomentosa had no significant effect on 
proliferation compared to untreated control cells (Figure 3.4). 
The growth of the non-malignant cells was completely reduced after treatment 
with the high dose of ethanolic Uncaria tomentosa extract compared to the low dose.  
Treatment of HBL100 cells with 1% of the ethanolic extract of Uncaria tomentosa for 5 
days decreased the cell number to below the starting concentration (Figures 3.5) while 
treatment of HEK293T cells decreased cell number by approximately 80% compared to   
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Figure 3.1. The effect of the ethanolic extract of Uncaria tomentosa on the 
proliferation of the malignant MCF7 cell line.  MCF7 cells were incubated with 
increasing concentrations of Uncaria tomentosa extracted with 70% ethanol, over 5 days 
and the cell growth was measured using the MTT assay. Absorbance at 540 nm was read 
each day. Mean values ± standard deviation (SD) for 8 separate measures are shown for 
each experiment. This data shows one representative experiments of at least 3 
independent experiments. The data were analyzed using graph pad prism and significant 
differences confirmed by ANOVA * (P < 0.05). 
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* 
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Figure 3.2. The effect of the PBS extract of Uncaria tomentosa on the 
proliferation of the malignant MCF7 cell line.  MCF7 cells were incubated with 
increasing concentrations of Uncaria tomentosa extracted with PBS, pH 7.4, over 5 days 
and the cell growth was measured using the MTT assay. Absorbance at 540 nm was read 
each day. Mean values ± standard deviation (SD) for 8 separate measures are shown for 
each experiment. This data shows one representative experiment of at least 3 independent 
experiments. The data were analyzed using graph pad prism and significant differences 
confirmed by ANOVA * (P < 0.05). 
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Figure 3.3. The effect of the ethanolic extract of U. tomentosa on the 
proliferation of the malignant MDA-MB-231 cell line. MDA-MB-231 cells 
were incubated with increasing concentrations of Uncaria tomentosa extracted with 70% 
ethanol, over 5 days and the cell growth was measured using the MTT assay. Absorbance 
at 540 nm was read each day. Mean values ± standard deviation (SD) for 8 separate 
measures is shown for each experiment. This data shows one representative experiment 
of at least 3 independent experiments. The data were analyzed using graph pad prism and 
significant differences confirmed by ANOVA * (P < 0.05). 
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Figure 3.4. Effect of the PBS extract of U. tomentosa on the proliferation of 
the malignant MDA-MB-231 cell line.  MDA-MB-231cells were incubated with 
increasing concentrations of Uncaria tomentosa extracted with PBS, pH 7.4, over 5 days 
and the cell growth was measured using the MTT assay. Absorbance at 540 nm was read 
each day. Mean values ± standard deviation (SD) for 8 separate measures per experiment. 
This data shows one experiments but 8 experimentations of at least 3 independent 
experiments. The data were analyzed using graph pad prism and significant differences 
confirmed by ANOVA * (P < 0.05). 
     
 38 
 
A 
         B              
Control 0.05% PBS 0.05% U. tomentosa extract 
 
Control 1% PBS 1% U. tomentosa extract 
 Abs
or
ba
nc
e 
at
 5
40
 n
m
 
 39 
       
Figure 3.5. Effect of the ethanolic extract of Uncaria tomentosa on the 
proliferation of the non-malignant HBL100 cell line.  HBL-100 non-cancer cells 
were incubated with increasing concentrations of Uncaria tomentosa extracted with 70% 
ethanol, over 5 days and the cell growth was measured using the MTT assay. Absorbance 
at 540 nm was read each day. Mean values ± standard deviation (SD) for 8 separate 
measures per experiment. This data shows one experiments but 8 experimentations of at 
least 3 independent experiments. The data were analyzed using graph pad prism and 
significant differences confirmed by ANOVA * (P < 0.05). 
 
 
 
 
   
 40 
A  
 
B 
     
Control 0.05% ethanol 0.05% U. tomentosa extract 
Control 1% ethanol 1% U. tomentosa extract 
* 
 41 
control (Figure 3.7) and treatment of HSG cells decreased cell number by more than 
70% (Figure 3.9). Treatment with both the high (1%) and low (0.05%) doses of the PBS 
extract did not cause a decrease in cell proliferation for the HBL100 (Figure 3.6), 
HEK293T (Figure 3.8), or HSG cells (Figure 3.10). 
In brief, the ethanolic extract of Uncaria tomentosa was able to effectively kill 
different cell types to a greater extent than the PBS extract (Figure 3.11). All 
experiments were run at least three independent times. In addition, the sensitivity to 
Uncaria tomentosa varied between cell lines. The largest effect of the ethanolic extract of 
Uncaria tomentosa was seen with HBL100 cells, as it caused a significant inhibition of 
cell proliferation by 83% (Figure 3.5). In addition, the ethanolic extract of Uncaria 
tomentosa caused a significant decrease in the growth of HEK 293T cells by 75% 
(Figure 3.7). 
3.2. Stability of both Uncaria tomentosa extracts.    
To test the stability of functioning components of Uncaria tomemtosa extracts, 
the ethanolic and PBS preparations were prepared and then stored at 4 °C.  Every week 
for four weeks the same experiment was performed: the  MCF7 cells were treated with 
different doses of Uncaria tomentosa extracts (0.05%, 1%) and cell number measured 
each day.  The antiproliferative effect of each extract was tested for 5 days using the 
MTT assay (Figure 3.12.). The results showed similar levels of cell growth inhibition for 
each of the four weeks, which indicated the stability of the active agents in the extracts. 
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Figure 3.6. Effect of the PBS extract of Uncaria tomentosa on the 
proliferation of the non-malignant HBL100 cell line.  HBL-100 cells were 
incubated with increasing concentrations of Uncaria tomentosa extracted with PBS, pH 
7.4, over 5 days and the cell growth was measured using the MTT assay. Absorbance at 
540 nm was read each day. Mean values ± standard deviation (SD) for 8 separate 
measures per experiment. This data shows one experiments but 8 experimentations of at 
least 3 independent experiments. The data were analyzed using graph pad prism and 
significant differences confirmed by ANOVA * (P < 0.05). 
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Figure 3.7. Effect of the ethanolic extract of Uncaria tomentosa on the 
proliferation of the non-malignant HEK 293T cell line.  HEK293T cells were 
incubated with increasing concentrations of Uncaria tomentosa extracted with 70% 
ethanol, over 5 days and the cell growth was measured using the MTT assay. Absorbance 
at 540 nm was read each day. Mean values ± standard deviation (SD) for 8 separate 
measures per experiment. This data shows one experiments but 8 experimentations of at 
least 3 independent experiments. The data were analyzed using graph pad prism and 
significant differences confirmed by ANOVA * (P < 0.05). 
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Figure 3.8. Effect of the PBS extract of Uncaria tomentosa on the 
proliferation of the non-malignant HEK 293T cell line.  HEK293T cells were 
incubated with increasing concentrations of Uncaria tomentosa extracted with PBS, pH 
7.4, over 5 days and the cell growth was measured using the MTT assay. Absorbance at 
540 nm was read each day. Mean values ± standard deviation (SD) for 8 separate 
measures per experiment. This data shows one experiments but 8 experimentations of at 
least 3 independent experiments. The data were analyzed using graph pad prism and 
significant differences confirmed by ANOVA * (P < 0.05). 
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Figure 3.9. Effect of the ethanolic extract of Uncaria tomentosa on the 
proliferative of the non-malignant HSG cell line. MCF7 cells were incubated 
with increasing concentrations of Uncaria tomentosa extracted with 70% ethanol, over 5 
days and the cell growth was measured using the MTT assay. Absorbance at 540 nm was 
read each day. Mean values ± standard deviation (SD) for 8 separate measures per 
experiment. This data shows one experiments but 8 experimentations of at least 3 
independent experiments. The data were analyzed using graph pad prism and significant 
differences confirmed by ANOVA * (P < 0.05). 
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Figure 3.10. Effect of PBS extract of Uncaria tomentosa on the proliferation 
of the non-malignant HSG cell line. HSG cells were incubated with increasing 
concentrations of Uncaria tomentosa extracted with PBS pH 7.4, over 5 days and the cell 
growth was measured using the MTT assay. Absorbance at 540 nm was read each day. 
Mean values ± standard deviation (SD) for 8 separate measures per experiment. This data 
shows one experiments but 8 experimentations of at least 3 independent experiments. The 
data were analyzed using graph pad prism and significant differences confirmed by 
ANOVA * (P < 0.05). 
 
 
   
 51 
 
A 
  
B  
     
Control 1% PBS 1% U. tomentosa extract 
Control 0.05% PBS 0.05% U. tomentosa extract 
 52 
      
Figure 3.11. Comparison of the effect of both extracts of Uncaria tomentosa 
on various cell lines.  Malignant and non-malignant cell lines were cultured for five 
days. Each day, the change in cell viability in response to treatments with the high 
concentration (1%) of both ethanolic and aqueous extracts of Uncaria tomentosa was 
assessed by MTT assay and compared. 
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Figure 3.12.  Stability of both Uncaria tomentosa extracts.   Each week, the 
effect of the Uncaria tomentosa ethanolic extract on MCF7 growth was examined for 
four weeks.  MCF7 cells were treated with the high and low dose of ethanolic extracts of 
Uncaria tomentos. The high dose of ethanolic extract of Uncaria tomentosa caused a 
significant decrease in the number of MCF7 cells by ~65%, 60%, 40%, 30% for week 1, 
week 2, week 3 and week 4, respectively  
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Figure 3.13.  Stability of both Uncaria tomentosa extracts.  Each week, the 
effect of the PBS extract of Uncaria tomentosa on MCF7 growth was examined for four 
weeks. MCF7 cells were treated with the high and low dose of the PBS extracts of 
Uncaria tomentosa. 
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3.3. Treatment with Uncaria tomentosa changed the morphology of 
malignant MCF7 cells 
The morphology of MCF7 cells was examined after treatment with Uncaria 
tomentosa extracts to determine if treatment caused any changes in the appearance of the 
cell cultures or in cell morphology. Treatment of the MCF7 cell cultures with different 
doses of Uncaria tomentosa extracts for 72 h had significant effects on the appearance of 
the cultures and on the morphology of the cells compared to cells treated with suspending 
media (Figure 3.14). Furthermore, there was a significant decrease in cell number in the 
treated cultures.  The control cultures (both ethanol and PBS suspending media) 
contained flattened cells at high confluence where there was little space between 
individual cells.  Treatment of the cells with the ethanolic extracts showed a decrease in 
the confluence of the cells corresponding to a decrease in cell number as well as a shift in 
the appearance of the cells to a more rounded appearance (Figure 3.14A). These changes 
in number, shape, and structure of the cells were most obvious when the high dose (1%) 
of ethanolic extract was added. In contrast to the high dose, cells treated with the low 
dose (0.05%) of the ethanolic extracts showed only a smaller change in cell morphology 
and cell confluence of the MCF7 cells compared to the control. Treatment with the PBS 
extacts of Uncaria tomentosa also affected MCF7 cultures (Figure 3.14B). Treatment 
with the high dose of Uncaria tomentosa PBS extracts (1%) showed a significant change 
in MCF7 cells and reduced cell viability, whereas treatment with the low concentration of 
PBS extracts (0.05%) did not show any significant effect on the cells compared to the 
control cells.  In brief, the morphology of treated cells significantly changed with 
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Figure 3.14. Treatment with Uncaria tomentosa changed the morphology of 
malignant MCF7 cells.  MCF7 cells were plated on 6 well plates and treated with the 
high dose and low dose concentration of Uncaria tomentosa extracts. Pictures were taken 
daily using an Inverted Phase Contrast Axiovert 100 Microscope (Zeiss Microscopes) 
and recorded using Northern Eclipse Software. The experiments were run in triplicate. 
Figure A is the ethanolic extract of Uncaria tomentosa. Figure B is the PBS extract of 
Uncaria tomentosa. 
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increasing concentration of both ethanolic and aqueous extracts of Uncaria tomentosa, 
after 72 hours. 
3.4. Treatment with Uncaria tomentosa changed the morphology of non-
malignant HEK293T cells 
Treatment of the HEK293T cell cultures with different doses of Uncaria 
tomentosa extracts for 72 h had similar effects to the effects on MCF7 cells (Figure 
3.15). The control cultures (both ethanol and PBS suspending media) contained flattened 
cells at high confluence where there was little space between individual cells.  Treatment 
of the HEK293T cells with the ethanolic extracts showed a decrease in the confluence of 
the cells corresponding to a decrease in cell number as well as a shift in the appearance of 
the cells to a more rounded appearance (Figure 3.15A). Cells treated with the high dose 
(1%) of ethanolic extract were much fewer in number and appeared very condensed in 
appearance. In contrast, cells treated with the low dose (0.05%) of the ethanolic extracts 
showed a decrease in confluence of the monolayer which was “patchy” in appearance 
when compared to the control. Treatment with the PBS extracts of Uncaria tomentosa 
also affected MCF7 cultures (Figure 3.15B). Treatment with the high dose of Uncaria 
tomentosa PBS extracts (1%) showed a significant change in HEK293T cells and reduced 
cell viability, whereas treatment with the low concentration of PBS extracts (0.05%) 
showed some areas of cell loss with the cells appearing to be less spread on the substrate. 
In brief, the morphology of treated cells significantly changed with treatment with 
extracts of Uncaria tomentosa. 
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Figure 3.15. Treatment with Uncaria tomentosa changed the morphology of 
non-malignant HEK 293T.  HEK 293T cells were plated on 6 well plates and treated 
with the high dose and low dose concentrations of Uncaria tomentosa extracts. Pictures 
were taken daily using an Inverted Phase Contrast Axiovert 100 Microscope (Zeiss 
Microscopes) and recorded using Northern Eclipse Software. The experiments were run 
in triplicate. Figure A is the ethanolic extract of Uncaria tomentosa. Figure B is the PBS 
extract of Uncaria tomentosa 
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3.5. Effect of Uncaria tomentosa extracts on MCF7 cell migration.   
The wound healing migration assay was used to determine the effect of Uncaria 
tomentosa on MCF7 cells behaviour.  MCF7 cells were plated on 6 well plates for 24 
hours then a wound of cleared cells was created in the monolayer with a 200 μl yellow 
pipet tip. The monolayers were treated with different concentrations of both the ethanol 
and PBS extracts of Uncaria tomentosa and digital photographs of the wounds taken at 
each day of treatment (day 4 is shown in Figure 3.16). Under normal culture conditions 
the cells migrate into the wound to recreate a confluent monolayer within 4 days.  
Camptothecin is a chemotherapy drug that promotes cell death and prevents cell 
migration and was used as positive control which showed no cell migration into the 
wound.  The cells treated with the high concentrations of either ethanolic or PBS 
preparations of Uncaria tomentos (1%) showed a significant decrease in cell migration as 
shown by the presence of a large gap in the monolayer after 4 days of culture.  The cells 
treated with the low concentration of the ethanolic extraction showed a small decrease in 
migration while the cells treated with the low concentration of the PBS extract looked 
very similar to the control cells.  The experiments were performed in triplicate and the 
width of the gap was measured each day and plotted to determine the effect of treatment 
on “wound healing” (Figure 3.17). Treatment with the high dose of the ethanolic extract 
showed significant inhibition of cell migration. Treatment with the high concentration of 
the PBS extract of Uncaria tomentosa also showed inhibition of MCF7 cell migration but 
to a lesser extent.    
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Figure 3.16. Effect of Uncaria tomentosa extracts on MCF7 cell migration.  
MCF7 cells were cultured on 6 well plates for 24 hours then a wound of cleared cells was 
created in the monolayer with a 200 μl yellow pipet tip. The cells were cultured in 
suspending media (control) or with the high concentrations of either ethanolic or PBS 
preparation of Uncaria tomentosa (1%) and the monolayers visualized each day for 5 
days.  The width of the gap was measured each day.  The images show the gap in the 
monolayer after 72 h of treatment.  Camptothecin was used as positive control since it is 
expected to induce cell death and prevent cell migration. The experiments were 
performed in triplicate.     
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Figure 3.17. Effect of Uncaria tomentosa extracts on MCF7 cells migration.  
A graphical representation of the effect of the Uncaria tomentosa extracts on wound 
healing of MCF7 cells as described in Figure 3.16.  
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3.6. Induction of apoptosis and DNA fragmentation following treatment 
with Uncaria tomentosa extracts 
A cell staining assay using acridine orange and ethidium bromide was used to 
examine the effect of Uncaria tomemtosa extracted with ethanol or PBS on the 
morphological changes in treated MCF7 cells. MCF7 cells were treated with a high dose 
(1%) of Uncaria tomentosa extracts then incubated for different durations (24 and 72 
hours) and digital photographs taken. Cells treated only with suspending media for 24 h 
show primarily nuclear staining with acridine orange and no ethidium bromide staining.  
Treatment with the high dose of ethanolic extracts for 24 h showed a change in cell 
morphology including changes in nuclear staining corresponding to condensation and the 
presence of some staining with ethidium bromide (Figures 3.18A and 3.19A).  MCF-7 
cells treated with the PBS extract for 24 h showed some smaller changes in nuclear 
staining but did not show ethidium bromide staining.  Cells treated with suspending 
media for 72 h also showed nuclear staining with acridine orange and no ethidium 
bromide staining which was very similar to the cells treated for 24 h.  MCF-7 cells 
treated with 1% ethanol extracts of Uncaria tomentosa showed significant nuclear 
fragmentation and apoptotic body formation as well as ethidium bromide staining of the 
nucleus (Figures 3.18B, 3.19B).  However, the treatment with high dose of Uncaria 
tomentosa PBS extracts for 72 hours showed an earlier stage of apoptosis as indicated by 
nuclear condensation and some nuclear fragmentation although there was very little 
ethidum bromide staining.  Cells treated with the chemotherapy drug, camptothecin 
showed significant nuclear condensation and fragmentation along with ethidium bromide 
staining and was used as a positive control for apoptosis.    
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Figure 3.18. Detection of apoptosis and DNA fragmentation in MCF 7 cells 
treated with Uncaria tomentosa using acridine orange and ethidium bromide 
staining.   MCF7 cells were cultured on glass coverslips and treated with the high 
concentration (1%) of Uncaria tomentosa extracted with PBS or ethanol and incubated 
for 24 and 72. Camptothecin was used a positive control to detect apoptosis. Cells were 
stained with a mixture of acridine orange and ethidium bromide for 10 min. The 
fluorescently labelled cells were visualized on an LSM 510 fluorescence microscope 
(Zeiss) and images obtained showing acridine orange (green), ethidium bromide (red), 
and phase contrast fields. Experiments were run in triplicate. Figure A is the ethanolic 
extract and PBS extract of Uncaria tomentosa for 24 hours.  Figure B is the ethanolic 
extract and the PBS extract of Uncaria tomentosa for 72 hours.  Images of Media and 
Camptothecin were taken after 24hours. 
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Figure 3.19. Detection of apoptosis and DNA fragmentation in MCF 7 cells 
treated with Uncaria tomentosa using acridine orange and ethidium bromide 
staining.    MCF7 cells were cultured on glass coverslips and treated with the high 
concentration (1%) of Uncaria tomentosa extracted with PBS or ethanol and incubated 
for 24 and 72. Camptothecin was used a positive control to detect apoptosis. Cells were 
stained with a mixture of acridine orange and ethidium bromide for 10 min. The 
fluorescently labelled cells were visualized on an LSM 510 fluorescence microscope 
(Zeiss) and images obtained showing acridine orange (green), ethidium bromide (red), 
and phase contrast fields. Experiments were run in triplicate. Figure A is the apoptotic 
cells after treatment with the high concentration of both extracts of Uncaria tomentosa 
for 24 hours.  Figure B is the apoptotic cells after treatment with the high concentration 
of both extracts of Uncaria tomentosa for 72 hours.  Images of media and camptothecin 
were taken after 24hours. 
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The TUNEL assay was used to detect apoptosis, which is characterized by DNA 
fragmentation that occurs during late apoptosis. MCF7 cells were treated with the high 
dose of both ethanol and PBS extracts of Uncaria tomentosa (1%) for 24 and 72 hours 
and then stained with the TUNEL reaction mixture. The presence of DNA fragmentation 
is seen as a green-stained nucleus as is present in the camptothecin-treated positive 
control cells.  Treatment of the cells with suspending media did not cause the cells to 
stain with the TUNEL reagent and there were very few stained cell present.  Treatment 
with the high dose of Uncaria tomentosa ethanolic extract for 24 h (Figure 3.20A) only 
showed a low level of TUNEL staining but treatment for 72 h caused a significant 
increase in TUNEL staining and DNA fragmentation where almost every cell was stained 
indicating induction of apoptosis after 72 hours of treatment (Figure 3.20B). Treatment 
with the high dose of the PBS extract for 24 hours showed only very low levels of 
staining with TUNEL while treatment for 72 h showed significant levels of staining in the 
majority of the cells. 
These results confirm our previous findings from the cell viability experiments 
that treatment of cells with Uncaria tomentosa decreased cell number by increasing 
cellular apoptosis, particularly for treatment with the ethanolic extracts of Uncaria 
tomentosa. 
  
 77 
  
 
 
 
Figure 3.20. Detection of apoptosis and DNA fragmentation in MCF 7 cells 
treated with Uncaria tomentosa using TUNEL staining.  MCF7 cells were 
cultured on glass coverslips and treated with different concentration (0.01% and 1%) of 
Uncaria tomentosa extracted with PBS or ethanol for 24 and 72 hours. MCF7 cells were 
treated with the high dose of Uncaria tomentosa extracts and incubated for 24 and 72 
hours. Cells were directly analyzed using a LSM 510 fluorescence microscope to detect 
labelled cells (green). Experiments were run in triplicate. The first panel displays TUNEL 
stain, the second panel displays MCF7 as seen under phase-contrast micrograph, and the 
third panel displays MCF7 with combined fluorescence and phase contrast microscopy. . 
Figure A is the ethanolic extract and PBS extract of Uncaria tomentosa for 24 hours.  
Figure B is the ethanolic extract and the PBS extract of Uncaria tomentosa for 72 hours.  
Images of Media and Camptothecin were taken after 24hours. 
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3.7. Detection of activated caspase-3, 8 and 9 in MCF7 cells treated with 
Uncaria tomentosa.  
The presence of activated caspase proteases is a measure of the activation of 
apoptosis.  To detect presence of active caspase -3, 8, and 9 in treated MCF7, a caspase 
activation assay was used. This assay measured the caspase enzyme activities that 
recognize and cleave the artificial substrates with the amino acid sequence, DEVD (for 
caspase-3), IETD (for caspase-8), and LEHD (for caspase-9). The activity of caspase-3, 
8, and 8 was associated with the release of p–Nitroanilid (pNA) from the labeled 
peptides. The cells were treated with suspending media, low dose (0.05%) and high dose 
(1%) of Uncaria tomentosa extracted with ethanol and incubated for 72 hours.  The 
treatment with the high dose of ethanol (1%) was previously shown to induce apoptosis. 
Duplicate cell plates were set up for each concentration. The increase in caspase-3, -8 and 
-9 activity was measured by comparison with un-induced control. MCF7 cells treated 
with the high dose of Uncaria tomentosa extracted with ethanol showed a significant 
increase in caspase 8 and 9 compare to control cells, with caspase 8 having the highest 
activity (Figures 3.21). However, cells treated with the high dose of ethanolic extracts of 
Uncaria tomentosa did not result in significant activation of caspase 3.   
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Figure 3.21. Detection of activated caspase -3,8, and 9 in treated MCF7 with 
Uncaria tomentosa extracted with ethanol.   A colorimetric assay was used to 
detect active caspase 3,8 and 9 in apoptotic cells using activation kits (Life Technology). 
MCF7 cells were treated with a low dose (0.05%) and a high dose (1%) of ethanolic 
extracts of Uncaria tomentosa for 72 hours. Cells were treated with 1% ethanol only as 
negative control for apoptosis. The increases in caspase activities were determined in 
triplicate by comparison of changes in absorbance at 410 nm using a (SpectraMax 340 
PC 389) plate reader.  Data for three independent experiments was normalized by setting 
the control activity to 1.0 (+ SD) and the fold change in activity (+ SD) determined for 
the treated cell samples.  * mark significant increases (p<0.05) in activity compared to 
control-treated cells.  The increase in activity of caspase-8 was the highest compared to 
the control cells.  
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 Chapter 4: Discussion 
Breast cancer is the most common disease-affecting woman in the world. 
Different therapies are recommended for breast cancer that can involve treatment with a 
single drug or a combination of drugs (Santose et al., 2012). However, the toxic side 
effects of these therapies are not selective for cancer cells and can affect normal tissues as 
well (Santose et al., 2012; Dreifuss et al., 2010). Therefore, the search for novel 
therapeutic approaches with low systemic toxicity is needed. Herbal medicines have 
gained more interest because they are thought to be less toxic and because several plant-
derived medicines have been identified, have been shown to have pharmacological 
properties, and have been shown to be promising agents to treat cancer and reduce the 
side effects of cancer therapies (Dreifuss et al., 2010).  
Uncaria tomentosa is one of the herbal medicines that have been consumed for 
decades because of its reputed anti-cancer and anti-oxidant properties. Uncaria 
tomentosa has been reported to reduce the side effects of chemotherapy in cancer 
patients. It also helps to restore cellular DNA, prevent cell damage, and decrease 
mutations caused by chemotherapy (Santose et al., 2012).   Uncaria tomentosa can also 
kill cancer cells or inhibit the growth of cancer cells with little toxicity to normal cells. 
My results showed the ability of Uncaria tomentosa extracts to inhibit cell growth of 
breast cancer cells in vitro as shown by the anti-proliferative effects.  
Uncaria tomentosa extracts from the bark and roots have been successfully 
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applied for inhibiting nitrite and TNF production that is related to immunomodulatory 
effects (Dreifuss et al., 2010).  Some researchers have reported that the anti-inflammatory 
activities possessed by Uncaria tomentosa could be related to a synergic combination of 
different compounds in the plant medicine (Dreifuss et al., 2010). 
Several experiments have been published that study the effects of Uncaria 
tomentosa on different cell lines. Sheng et al (1998) has suggested that treatment with the 
aqueous extracts of Uncaria tomentosa significantly reduced the proliferation of HL60 
human leukemia cells. Treatment also enhanced DNA repair activity. Furthermore, the 
(C-Med-l00) aqueous extract from Uncaria tomentosa inhibited the proliferation of 
tumour cells by inducing apoptosis in vitro and by improving the immune response and 
increasing white blood cells in vivo as observed in both human volunteers and rats 
supplemented with the aqueous extract (Sheng et al., 2001; 2000). 
Riva et al (2001) were the first that demonstrated the effects of treatment with 
Uncaria tomentosa bark extractions and fractions on the MCF7 breast cancer cell line 
(Dreifuss et al., 2010). More results from this study suggested that Uncaria tomentosa 
had anti-proliferative effects against neoplastic tumours.  More recently, researchers have 
stated that mitraphylline, a component of Uncaria tomentosa, has anti-tumour activity on 
human cellular neuroblastoma and glioma cells in vitro (Dreifuss et al., 2010).  
 4.1 Effects of Uncaria tomentosa extracts on cell proliferation  
The anti-proliferative effects of Uncaria tomentosa have been confirmed in many 
studies on different cell lines (De Martino et al., 2006).  Prado’s study reported the dose –
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dependent anti-proliferative and cytotoxic activities of mitraphylline pentacyclic alkaloid 
isolated from Uncaria tomentosa on human neuroblastoma SKN-BE and glioma GAMG 
cells (Prado et al., 2007).  
  Rinner’s study found anti-proliferative effects of Uncaria tomentosa extracts 
against medullary thyroid carcinoma (MTC) cells and anti-enzyme activities against 
mitochondrial dehydrogenase after three days of treatment. Further, Rinner’s study found 
that the alkaloids, isopterpodine and pteropodine, significantly induced pro-apoptosis in 
MTC-SK cells that were derived from a solid tumour. Moreover, treatment with Uncaria 
tomentosa extracts of isopterpodine and pteropodine showed a dose and time–dependent 
increase in the expression of caspase-3 and caspase-7 while the level of bcl2 stayed 
constant (Rinner et al., 2009).   
 Pilarski’s study reported the effects of different preparations of Uncaria 
tomentosa on the proliferation of HL-60 promyelocytic leukemia cells (Pilarski et al., 
2007). In Pilarki’s study, the MTT assay (thiazolyl blue tetrazolium bromide) was used to 
determine cell viability after treated with different preparations of Uncaria tomentosa. 
The MTT assay, which was also used in my experiments, is based on formation of dark 
purple formazan crystals from soluble MTT salts by the mitochondrial enzymes of living 
cells (Sylvester, 2011).  The results from the MTT assay indicated that the ethanolic 
preparation had a higher cytotoxic effect than the aqueous extract of Uncaria tomentosa 
since it suppressed the proliferation of HL-60 cells more than aqueous preparation after 
exposure to preparations for 24, 48 and 72 hours (Sylvester, 2011). 
In the present study, MTT assays were conducted over five days to measure the 
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proliferation rate of different cell lines after treatment with two preparation of Uncaria 
tomentosa: ethanolic and aqueous. The results showed that treatment with Uncaaria 
tomentosa extracts killed the tumor cell lines and non- malignant cell lines with the same 
efficacy which indicated the unselectively character of Uncaria tomentosa. Moreover, the 
results showed a complete inhibition of cell proliferation after exposure to the highest 
concentration (1%) of the Uncaria tomentosa ethanolic extract in both malignant cells  
(MCF7, MDA-MB-231) and non-malignant cells (HBL100, HEK239T and HSG). 
However, the highest concentration (1%) of the PBS preparation of Uncaria tomentosa 
caused a significant, but incomplete, reduction in cell proliferation of malignant cells, but 
not in non-malignant cells, which keep growing after treatment with various doses of 
Uncaria tomentosa extracted with PBS. This indicated that both extracts had anti-
proliferative potency. However, Uncaria tomentosa extracted with 70% ethanol had 
strongest anti-proliferative effect due to the different compounds in both extractions. The 
ethanolic extract was much more effective as the cells showed the highest mortality after 
exposure to it. Indeed, the ethanolic extract may be enriched with petropedine and 
isopterpodine, which could be active inducers of apoptosis in MCF7 cells, a phenomenon 
which requires further investigation going forward.  
In Rinner’s study, the morphology of MTC-SK cells was changed after treatment 
with Uncaria tomentosa extracts isopterpodine and pteropodine as measured by 
chromatin condensation, cell shrinking and apoptotic bodies (Rinner et al., 2009).  Future studies to determine if these components also moderate the changes in cell proliferation should be performed.  
In our study, there were morphological changes in all of cell lines tested after 
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treatment with the high concentrations of Uncaria tomentosa extracts. There was 
significant damage to the MCF7 cells as indicated by differences in cell shape and the 
decrease in cell number after treatment with 1% of Uncaria tomentosa ethanol extracts 
by 72 hours. However, treatment with the high dose of PBS extract was less effective 
than the ethanolic extract in MCF7 cells in terms of changes in cell shape and number. 
This supports the potency of the ethanolic extracts of Uncaria tomentosa as an anti-
cancer drug.   
Additional confirmation was done using a wound healing migration assay to 
demonstrate the effects of Uncaria tomentosa extracts on MCF7 cell migration in vitro. 
The wound healing migration assay measures the ability of the cells to migrate into and 
fill a wound created by “ scratching” a cell monolayer.  There was an obvious reduction 
of MCF7 migration into the wounded area when the cells were treated with the high 
concentration of ethanol extracts of Uncaria tomentosa.  This effect is dose-dependent, as 
the low dose of the ethanolic extract showed minimal MCF7 migration. The high dose of 
PBS extract caused less migration than the high dose of ethanol, while no migration was 
visible with the low dose of PBS extract. This emphasizes the potent effects of the 
alcoholic extracts of Uncaria tomentosa on tumor cells.  
4.2 Induction of Apoptosis by Uncaria tomentosa  
Plant-derived components have played a critical role for long time in treatments 
against cancer particularly by inducing death in malignant cells through the induction of 
apoptosis.  It has become increasingly evident that plant- derived drugs may be valuable 
in the prevention and treatment of cancer (Taraphdar et al., 2001).  Many studies suggest 
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that plant-derived natural products contain various anti-cancer components with different 
mechanisms of action, but almost all are based on their ability to induce apoptosis 
(Taraphdar et al., 2001). Our findings confirm that treatment with Uncaria tomentosa 
ethanol extracts can induce apoptosis in breast cancer cells. 
Many experiments were done to investigate the mode of action of Uncaria 
tomentosa and measure various features of apoptosis including acridine orange/ethidium 
bromide staining and TUNEL assays. Acridine orange /ethidium bromide staining is a 
morphological staining to detect apoptotic morphology of cells in vitro (Ribble et al., 
2005). Acridine orange stains nucleic acids (in particle nuclei) in both live and dead cells 
and early apoptotic cells show structural changes in the green-stained nucleus (Kasibhatla 
et al., 2006), while ethidium bromide stains only dead cells with compromised-plasma 
membranes allowing the nucleus to stain red.  
An apoptotic cells shows condensed and fragmented staining of the nuclei (green) 
with no ethidium bromide staining. However, late in apoptosis, the plasma membrane 
breaks down and the cells also stain red. Our results showed an early apoptosis was 
introduced in a small number of cells after 24 h in MCF7 treated with the high dose of the 
ethanolic extract of Uncaria tomentosa. In contrast, the high dose of PBS did not show 
any early apoptotic features by 24 h. However, treatment with either extract of Uncaria 
tomentos caused chromatin condensation and late apoptosis by 72 hours although the 
number of affected cells was increased in cells treated with the ethanol extract. The 
ethanolic extract was much more effective than the PBS extract of Uncaria tomentosa at 
inducing apoptosis. 
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An additional assay was performed to detect apoptosis- related extensive DNA 
fragmentation. The TUNEL DNA fragmentation assay used terminal transferase to 
transfer a labelled nucleotide to any available DNA end. When DNA fragmentation 
occurs the number of free DNA ends increases dramatically and the presence of labelled 
DNA increases. Therefore, in the experiments, the MCF7 cells were treated with Uncaria 
tomentosa extracts for 1-3 days and labelled using TUNEL reactions.  The results 
presented a significant increase in apoptotic cells due to DNA fragmentation after 72 h in 
MCF7 cells treated with the ethanolic extract of Uncaria tomentosa that was greater than 
that seen for the PBS extract. This confirms the effectiveness of ethanolic extract of 
Uncaria tomentosa.   
Similar results were found in other studies in the laboratory that measured the 
effects of Uncaria tomentosa extracts on B16-BL6 cells. The results showed that 
treatment with Uncaria tomentosa extracts greatly induced DNA fragmentation and 
increased the number of apoptotic cells in B16-BL6 cells treated with 200 μg/ml of 
Uncaria tomentosa extracted with ethanol (Zari A, 2014).  
Since the ethanolic extract of Uncaria tomentosa showed a significant induction 
of apoptosis, a caspase activity assay was done to confirm that the ethanolic extract 
mediated MCF7 cell killing via apoptosis. Apoptosis is characterized by activation of 
caspases (Zhang et al., 2011).  In addition, the activation of specific caspases can indicate 
the pathway by which apoptosis is activated: the extrinsic pathway which involves 
activation of “ death receptors” on the cell surface results in activation of caspase-6 and-8 
while activation of the intrinsic pathway following disruption of the mitochondria often 
as a result of Bcl-2 family protein interactions results in activation of caspase-9. Another 
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study suggested that Uncaria tomentosa greatly increased the activity of caspases 8, 1 
and of the effector caspase 3 in HT29 cells (de Oliveira et al., 2014).  
The results of these studies showed that MCF7 cells exposed to various 
concentrations of Uncaria tomentosa extracted with ethanol for 72 h caused a significant 
increase in the activity of caspase-8 and caspase-9 compared control. This indicates that 
Uncaria tomentosa extracts induced apoptosis by activation of both intrinsic and extrinsic 
pathways. The level of caspase-3 activation was relatively low and was not induced by 
treatment with Uncaria tomentosa extracts.  Since MCF7 cells have been shown to be 
genetically deficient in the caspase-3 gene, it is not surprising there is low caspase-3 
activity.   
Overall, our result confirmed the anti-proliferative effects of both Uncaria 
tomentosa extracts against malignant and non-malignant cells. The ethanol extract was 
more potent than the PBS extract and showed significant results against MCF7 cells in 
terms of inhibition of cell growth and induced apoptosis. This could be due to different 
active component in both extracts. 
Aguilar study’s had similar results and demonstrated that both extracts of Uncaria 
tomentosa bark have an anti-inflammatory activity. The tested hydroalcoholic extract was 
more effective, which suggested that this effectiveness could be because of the presence 
of pentacyclic OAs acting alone or with other metabolites (Aguilar et al., 2002).   
 4.3. Conclusion 
Plant derived component have played a critical role in improve health for a long 
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time. Uncaria tomentosa is one of the natural medicines has been used for decades for 
it’s pharmological prosperities.  Our present results showed that ethanolic extract of 
Uncaria tomentosa caused significant inhibition in terms of cell growth and number of 
both malignant and non-malignant cells in vitro by72h.  Also, it also induced morphology 
changes in MCF7 cells. However, the PBS extract was able to decrease the cell 
proliferation of malignant cells but to a lesser extract. Moreover, further confirmations 
were done using assay such as TUNEL assay and acridine orange/ethidium bromide 
staining. The results showed an increased in DNA fragmentation and apoptotic cells in 
MCF7 cells treated with both extracts particularly ethanolic extract. Since the ethanolic 
extract was more effective, a caspase activity assay was performed to emphasize the 
apoptosis. The data confirmed that MCF7 cells were undergoing apoptosis. Overall, The 
treatment with both extracts of Uncaria tomentosa caused major inhibition in cell 
proliferation of malignant and non-malignant cell lines. Furthermore, the ethanol extract 
derived from Uncaria tomentosa showed a significant inhibition of MCF7 cells in a dose-
dependent manner and its effect was stronger than the PBS extract. Therefore, further 
testing required in different neoplastic cells in the future in order developing a novel 
anticancer drug. 
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